sustain growth strategi innov lead strong perform
downgrad rate hold maintain
tp provid upsid potenti
deriv estim base forward earn
multipl ep estim top-
line revenu grow
re-initi coverag plc
last coverag report septemb estim tp
base forward price-to-earnings multipl ep
maintain tp
perform per expect sold patient deep
vein thrombosi nutrit insuffici busi juli
result flat growth
estim base follow factor strong second
half perform due sustain growth strategi innov
global market penetr double-digit growth emerg
market strong growth diabet group cvg segment
plc deliv strong fourth quarter result
expand oper margin double-digit growth ep
oper margin grew ep grew
net revenu increas organ
deliv strong second half perform
overcom challeng first half includ
disrupt multipl hurrican fire santa rosa suppli
constraint diabet
deliv double-digit growth emerg market
increas y/i total revenu increas
compani name plc ordinari sharestickermdtstock ratingholddowngradeindustri viewneutralunchangedpric june week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth plc juli
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
diabet group double-digit organ growth
growth due increas demand
hybrid close loop insulin pump rtg
segment best quarter revenu growth
histori due continu strength brain pain therapi
complet covidien synergi commit
return sharehold confid
deliv oper leverag margin expans
launch new enterpris excel program increas
effect drive continu save enabl
reinvest growth
expect revenu grow rang
organ adjust ep expect grow
rang
mdt ytd stock perform compar
 roe roa ttm basi
medtron current price-to-earnings averag price-to-earnings
price-to-earnings show huge fluctuat last three
year due volatil stock price price-to-earnings reach
average stdev past three year
also went average stdev past three year
expect forward price-to-earnings multipl
expect grow base
perform growth strategi expect ep
estim tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date last split factor new per last split date sep inform medtron plc juli
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net net incom avail common earn per weight averag share estim annual actual annual actual quarterli plc juli
cash short-term total prepaid current total current net properti plant intang long-term total non-curr total short-term capit account defer incom tax accru current total current long-term capit defer tax pension minor long-term total non-curr total addit paid-in retain accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli plc juli
flow oper activ decreas compar
decreas due increas cash paid tax increas net cash outflow collater
relat deriv instrument cash paid divestiture-rel expens
increas certain litig payment decreas cash collect custom
provid invest activ compar net cash use invest activ
increas due sale patient deep vein thrombosi nutrit
insuffici busi juli result net proce decreas cash paid
acquisit decreas addit properti plant equip
provid financ activ increas compar due
repay unsecur term loan
depreci invest loss defer incom stock base chang work account work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt common stock common stock dividend financ net cash provid use financ effect exchang rate net chang begin end free oper cash capit free cash plc juli
result overview
public limit compani incorpor june
medic technolog servic solut compani allevi pain restor
health extend life million peopl around world medtron
develop manufactur market medic devic technolog
hospit physician clinician patient countri mdt subsidiari
includ inc heartwar intern inc
net revenu increas compar
revenu increas organ basi adjust
divestitur patient deep vein thrombosi compress nutrit
insuffici busi cardin occur
posit impact foreign currenc
net revenu increas due growth diabet group reflect us
patient demand hybrid close loop system also due
growth rtg busi due double-digit growth neurovascular
neurosurgeri pain therapi rtg segment best quarter organ
growth histori
net revenu increas
compar
total revenu
repres total
revenu
total revenu repres total revenu total
revenu non-u develop market repres total revenu
total revenu emerg market repres total revenu
distributionu semerg marketsnon-u develop market total revenu
increas
compar
gaap ep increas
compar
increas
compar
result overview
total revenu declin compar
total revenu non-u develop market increas
compar total revenu
emerg market increas compar
cog decreas compar
 expens increas compar
sg expens increas compar
net incom increas compar
non-gaap net incom increas
compar prior year period
gaap ep increas compar
non-gaap ep increas compar prior year
net revenu increas compar
revenu increas organ basi adjust
divestitur acquisit posit impact foreign currenc
total revenu decreas compar
total revenu non-u develop market increas
compar total revenu
emerg market increas compar
cog decreas compar cog
total revenu compar total revenu
decreas due divestitur lower-margin product conjunct
divestitur patient deep vein thrombosi nutrit
result overview
 expens increas compar
 expens rel flat compar prior year period
sg expens increas compar
sg expens increas compar
due expens incur associ new product launch
effect tax rate compar
increas effect tax rate due impact tax reform
divestitur patient deep vein thrombosi nutrit insuffici
busi util non-u special deduct net tax cost
associ intern reorgan excess tax benefit associ
stock-bas compens tax effect inter-company sale
non-gaap tax rate compar
decreas non-gaap tax rate due oper tax benefit year-
over-year chang oper result jurisdict
net incom decreas compar
non-gaap net incom increas compar prior
gaap ep decreas compar non-
gaap ep increas compar prior year period
gaap ep unfavor affect net tax charg relat
enact tax cut job act tax act invest loss
relat impair certain cost equiti method invest
along impair ipr also due sale
patient deep vein thrombosi nutrit insuffici busi
within minim invas therapi group
increas
compar
due expens
incur associ
new product
launch transit
gaap ep decreas
compar
increas
compar
segment perform
oper four segment cardiac vascular group cvg minim
invas therapi group mitg restor therapi group rtg diabet
group cvg segment contribut revenu mitg segment contribut
revenu rtg segment contribut revenu diabet segment
contribut revenu
revenu mitg
revenu rtg segment
contribut
revenu diabet
revenu
cardiac vascular group cvg cardiac vascular group segment
includ cardiac rhythm heart failur crhf coronari structur heart
csh aortic peripher vascular apv crhf contribut segment
revenu apv contribut segment revenu csh contribut
segment revenu
segment perform
cardiac vascular group cvg
cardiac vascular group segment revenu increas
compar cvg segment revenu
increas compar
cvg revenu perform driven strong low-teen growth csh mid-
singl digit growth apv low-singl digit growth crhf constant
cvg revenu increas compar
total revenu increas
compar
cvg revenu non-u develop market increas
compar total revenu non-u
develop market increas compar
cvg revenu emerg market increas
compar total revenu emerg market
increas compar
develop manufactur market product diagnosi treatment
manag heart rhythm disord heart failur product includ
implant devic lead deliveri system product treatment atrial
fibril af product design reduc surgic site infect inform
system manag patient crhf devic integr
crhf revenu increas compar
total revenu increas compar
cardiac vascular
increas
compar
compar
segment perform
cardiac vascular group cvg
growth driven lsd growth arrhythmia manag high-singl
digit growth pace led strong adopt micra transcathet
pace launch azur wireless pacemak result
also driven doubl digit growth mechan
circulatori support tyrx infect control
therapi treat coronari arteri diseas cad heart valv disord
product includ coronari stent relat deliveri system includ line
accessori well product repair replac heart
valv perfus system posit stabil system beat heart
revascular surgeri surgic ablat product
csh revenu increas compar
total revenu increas compar
csh revenu increas
compar
increas
compar
csh revenu increas due continu strong custom adopt
evolut transcathet aortic valv system evolut evolut
transcathet aortic heart valv well continu penetr
intermedi risk receiv approv late net
sale growth also driven continu strong demand
resolut onyx drugelut stent japan launch
aortic peripher vascular diseas manag apv apv divis consist
line product therapi treat aortic diseas aneurysm
dissect transect well peripher vascular diseas pvd
peripher drug coat balloon stent angioplasti system carotid
embol protect system treatment vascular diseas outsid
heart product line includ rang endovascular stent graft
accessori includ endur abdomin aortic aneurysm aaa stent
graft system valiant captivia thorac aortic aneurysm taa stent graft
segment perform
cardiac vascular group cvg
apv revenu increas compar
total revenu increas compar
apv revenu increas due growth valiant captivia thorac stent
graft percutan translumin angioplasti pta balloon drug-
coat balloon well success heli-fx endoanchor net
sale growth driven strong perform endoven due
acceler growth venas vein closur system approv
reimburs payment center medicar
medicaid servic initi januari
segment includ surgic innov si respiratori gastrointestin
renal divis si divis contribut revenu
divis contribut revenu
compar
compar
mitg revenu declin compar
total revenu declin compar
segment perform
mitg revenu perform driven mid-singl digit growth si
low-singl digit growth compar constant currenc
basi mitg net revenu affect divestitur patient
deep vein thrombosi nutrit insuffici busi juli
subsequ divestitur surgic solut
patient monitor recoveri divis realign surgic
innov respiratori gastrointestin renal divis
mitg revenu declin compar
total revenu declin
compar
mitg revenu non-u develop market rel flat
compar prior year period total revenu non-
 develop market declin compar
mitg revenu emerg market increas
compar total revenu emerg
market increas compar
surgic innov si si divis develop manufactur market
product therapi treat diseas condit address
surgeon surgic innov busi includ sale stapl vessel seal
fixat hernia mechan devic mesh hardwar surgic instrument
sutur electro surgeri product
si divis revenu increas constant currenc basi
compar prior year period total revenu increas
compar prior year period
mitg revenu
declin
compar
increas
compar prior year
segment perform
surgic innov revenu due new product advanc
stapl advanc energi includ signia power surgic stapl
system endo stapl specialti reload also valleylab energi
platform new iter ligasur vessel seal instrument
growth emerg market
respiratori gastrointestin renal divis consist
respiratori monitor solut renal solut busi
respiratori monitor solut busi includ patient monitor
respiratori solut advanc ablat gi solut product line
renal solut busi includ renal access dialyz product
revenu increas compar constant currenc basi
compar prior year period total revenu
decreas compar prior year period
revenu declin result juli divestitur
patient deep vein thrombosi nutrit insuffici busi
year revenu benefit growth gi solut
strength nellcor puls oximetri product due intens flu
season continu adopt microstream capnographi
monitor product growth airway ventil net sale
quarter
restor therapi group rtg rtg includ spine brain therapi
specialti therapi pain therapi divis spine divis contribut
revenu brain therapi contribut revenu specialti therapi
contribut revenu pain therapi contribut revenu
currenc basi
compar
revenu decreas
compar prior year
segment perform
compar
rtg revenu non-
increas
compar
rtg revenu increas compar
total revenu increas compar
rtg revenu increas due strong growth brain therapi solid
growth specialti therapi pain therapi
rtg revenu increas compar
total revenu increas
compar
rtg revenu non-u develop market increas
compar total revenu non-u
develop market increas compar
rtg revenu emerg market increas
compar total revenu emerg market
increas compar
segment perform
spine spine divis develop manufactur market line medic
devic implant use treatment spine musculoskelet
system product therapi treat rang condit affect spine
includ degen disc diseas spinal deform spinal tumor fractur
spine stenosi spine divis also provid biolog solut
orthoped dental market concert surgic technolog
busi offer navig neuromonitor power technolog design
spine procedur
spine revenu increas compar
total revenu increas compar
spine revenu increas due growth bone morphogenet protein
partial off-set slight declin spine spine net sale
declin due continu overal market soft europ
partial off-set continu success surgic synergi strategi
integr spinal implant enabl technolog imag
navig power instrument nerv monitor mazor robot sold
neurosurgeri busi speed-to-scal initi involv faster
innov cycl launch steadi cadenc new product
scale set immedi avail entir market
brain therapi brain therapi divis develop manufactur
market product therapi treat diseas vasculatur around
brain product includ coil neurovascular stent flow divers
product well access deliveri product support procedur
product offer includ pipelin pipelin flex embol devic
endovascular treatment larg giant wide-neck brain aneurysm
solitair fr revascular devic treatment acut ischem stroke
apollo onyx deliveri micro cathet
brain therapi revenu increas compar
total revenu increas
compar
compar
revenu increas
compar
increas
compar
increas
revenu due
growth ent pelvic
segment perform
brain therapi revenu increas due strong growth neurovascular
neurosurgeri neurovascular net sale growth driven strength
across stroke portfolio specif stent result lead role
develop endovascular therapi market treatment ischem
neurosurgeri net sale growth driven strong sale stealthstat
mri-guid laser ablat system mida dispos well dispos
revenu placement capit equip distributor agreement
mazor net sale growth partial off-set slight declin brain
modul due competit pressur major market
specialti therapi specialti divis develop manufactur market
product therapi treat diseas condit ear nose throat
ent certain neurolog disord addit divis develop
manufactur market image-guid surgeri intra-op imag
system facilit surgic plan precis cranial spinal sinu
specialti therapi divis revenu increas
compar total revenu increas
compar
increas revenu due growth ent pelvic health
target drug deliveri system manag chronic pain common
movement disord spastic urolog gastrointestin disord
portfolio neurostimul system includ recharg non-
recharg devic select lead use treat chronic back and/or
limb pain portfolio product includ pain neurostimul system
surescan includ restoresensor recharg surescan
mri adaptivestim technolog devic use treat chronic
intract pain sever spastic associ cerebr palsi multipl
sclerosi spinal cord traumat brain injuri stroke
increas
compar
revenu increas
compar
segment perform
pain therapi revenu increas compar
total revenu increas
compar
pain therapi divis strong mid-teen growth pain stimul
strength recent launch intelli platform spinal cord
stimul along on-going global roll-out evolv workflow
diabet group diabet group includ intens insulin manag
iim diabet servic solut dss non-intens diabet therapi
ndt divis diabet group divis develop manufactur market
integr diabet manag solut includ insulin pump therapi
continu glucos monitor cgm system therapi manag softwar
diabet group revenu increas
compar total revenu increas
compar
diabet group growth due increas sale due
continu growth custom base continu adopt
minim hybrid close loop system continu growth
intern market due strong sale minim system
europ asia pacif
diabet group revenu increas
compar total revenu increas
compar
diabet group revenu non-u develop market increas
compar total revenu
non-u develop market increas
compar
diabet group revenu emerg market increas
compar total revenu
emerg market increas compar
grew high-
twenti constant
currenc basi driven
 launch
system
segment perform
iim revenu grew high-twenti constant currenc basi
driven launch minim hybrid close loop insulin
pump system guardian sensor continu glucos monitor cgm
continu strength minim system
dss fourth quarter revenu grew low-doubl digit constant
currenc basi strong growth consum benefit custom
base growth improv patient util
ndt fourth quarter revenu declin low twenti constant
currenc basi given commerci focu minim launch
industri leader technolog
continu innov enhanc clinic outcom econom
valu exist product
invent creat develop new therapi result new market
disrupt disrupt therapi exist market redefin
medtron long-rang plan drive sharehold valu
sustain growth innov global
leverag size scale drive margin expans growth
improv oper cash flow increas disciplin account
disciplin approach increas return drive long-term valu
posit deliv sustain revenu growth diversifi
revenu base develop market expect grow rang
organ emerg market expect low double-digit organ
growth cvg segment mitg segment rtg segment expect grow
develop market diabet group expect grow emerg
launch new enterpris excel program increas
effect drive continu save enabl reinvest growth
global oper integr evolv global oper improv qualiti
deliveri cost cash flow
function optim evolv global function support long-term growth
sustain product
commerci optim oper commerci organ scale
improv custom servic experi
technolog drive mix shift faster growth market
focus increas weight averag market growth rate
anoth strong quarter
continu execut
sustain growth
innov global
deliv
enterpris synergi
sale growth estim organ impli
revenu growth rate
oper margin expect
adjust ep expect growth
tax rate expect
free cash flow expect
medtron deliv anoth strong quarter continu execut
sustain growth strategi drive therapi innov global market
penetr deliv enterpris synergi expand margin net
revenu increas revenu increas due
double-digit growth diabet group also double-digit growth emerg
total revenu emerg market increas
compar diabet group revenu increas
revenu increas
diabet group growth due increas demand product minim
gaap ep increas non-gaap ep increas
ep decreas due
increas tax rate non-gaap ep increas
free cash flow oper includ ir pre-
payment puerto rico paid dividend repurchas
share complet covidien synergi commit
launch new enterpris excel program increas effect drive
continu save enabl reinvest growth
ytd stock perform compar roe
roa ttm basi
non- reconcili
non- reconcili
non- reconcili
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas compar due decreas cog
oper margin rel flat
ep growth declin compar due decreas net margin
due increas tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth plc juli
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale medtron plc juli
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqcapex salescap ex salesfre mrqreturn asset medtron plc juli
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item medtron plc juli
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free plc juli
medtron current price-to-earnings averag price-to-earnings price-to-earnings show huge fluctuat
last three year due volatil stock price price-to-earnings reach average stdev past
three year also went average stdev past three year expect forward price-to-earnings multipl
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdershar report outvaluevanguard group inc wellington manag compani massachusett servic capit research global price row associ lazard asset manag artisan partner limit top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard specialized-health vanguard/windsor vanguard institut fund-institut mf seri trust i-mf valu vanguard specialized-dividend appreci vanguard/wellington fund invest compani competit
developmentsartifici intelligence-pow sugar iq tm diabet manag app develop watson commerci availablejun plc strateg technolog partner watson announc commerci avail sugar iq tm smart diabet assist first-of-its-kind intellig app design simplifi improv daili diabet manag groundbreak sugar iq smart diabet assist leverag artifici intellig ai analyt technolog watson continu analyz individu glucos level respond food intak insulin dosag daili routin factor inform provid app user receiv fda approv new pediatr indic minim tm hybrid close loop system children age plc announc food drug administr fda approv use minim tm system patient type diabet seven year age older newest system featur advanc smartguard tm technolog accur cgm guardian sensor work togeth autom deliveri person amount basal insulin everi five minut base sensor glucos valu system constantli self-adjust help avoid high low allow patient spend time rang percentag time spent optim glycem rang mg/dl independ stent imag studi show excel heal profil resolut onyx de complex patient coronari arteri diseasemay unveil clinic data independ run onyx oct studi show strong earli vessel heal patient popul contain high percentag patient complex coronari arteri diseas implant resolut onyx tm de one-month follow-up present europcr annual meet pari data patient includ acut coronari syndrom ac evalu use optic coher tomographi oct light-bas intracoronari imag provid extrem high-qual imag coronari wall especi structur closest vessel lumen onyx oct studi patient implant resolut onyx de demonstr excel earli heal profil averag percent strut cover neointim format new cell growth stent strut percent total stent area show complet strut coverag one month includ cover area strut announc fda approv infus tm bone graft new spine surgeri indic use peek interbodi implantsapril plc announc food drug administr fda approv infus tm bone graft new spine surgeri indic infusebon graft approv use addit spine implant made polyetheretherketon peek obliqu later interbodi fusion olif olif anterior lumbar interbodi fusion alif procedur singl level second expand indic two year plc juli
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
compar
sale growth
ttm compar
industri averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit plc juli
consensu view analyst trend stock
forecast vs
forward price-to-earnings
compar
mdt avgfive-year growth forecast usdgrowth high day day day estim comparisonmdtindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
price target summarycrispidea isi americaupgradeneutr sach initiatedneutralrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext plc juli
incom statement
result
segment
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock movement volatil show upward trend may
current trade
stock gave return last three month
stock gave rel flat return year show huge fluctuat year
face challeng tri overcom
stock dip surg januari dividend grow
stock rang stock
stock show huge fluctuat last three year gave return last
stock dip surg june
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
